Clinical TrialMay 11, 2026, 07:05 AM
Invivyd: Antibody Shows 2% AEs vs. 91.6% for mRNA COVID Vaccine
AI Summary
Invivyd, Inc. announced new research demonstrating significantly higher tolerability for its investigational monoclonal antibody adintrevimab compared to mRNA and protein-based COVID-19 vaccines. A post-hoc re-analysis of the EVADE trial showed only 2% Grade 2/3 systemic adverse events for adintrevimab within seven days, versus 91.6% for mRNA vaccines and 83.6% for protein vaccines. This research, available on MedRxiv, highlights the public health challenge of vaccine-induced symptoms. Invivyd plans to build on these findings with the upcoming LIBERTY trial, a head-to-head study comparing VYD2311 (a descendant of adintrevimab) with an mRNA vaccine.
Key Highlights
- Invivyd's new research preprint on MedRxiv compares COVID monoclonal antibody and vaccine systemic reactogenicity.
- Adintrevimab (monoclonal antibody) showed 2% Grade 2/3 systemic adverse events (AEs) in the first 7 days post-dosing.
- mRNA vaccine showed 91.6% Grade 2/3 systemic AEs in the first 7 days post-vaccination.
- Protein vaccine showed 83.6% Grade 2/3 systemic AEs in the first 7 days post-vaccination.
- mRNA vaccine symptoms lasted 3.5 days, while protein vaccine symptoms lasted 3.1 days.
- Invivyd anticipates starting the LIBERTY study, a head-to-head trial comparing VYD2311 and mRNA vaccine tolerability.
- The LIBERTY trial is expected to enroll approximately 210 participants.
Price Impact
More from IVVD